TP53 mutations occur in approximately 8%-14% of de novo MDS patients [307, 520–522], whereas it increases in therapy-related MDS (t-MDS), approaching 38% [304, 306, 521–523]. This evidence concerns the gene TP53 and myelodysplastic syndrome.